Europese Unie - Nederlands - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunosuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - bloedarmoede, sikkelcel - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - immunosuppressiva - plaque psoriasistaltz is geïndiceerd voor de behandeling van matige tot ernstige plaque psoriasis bij volwassenen die in aanmerking komen voor systemische therapie. psoriatica arthritistaltz, alleen of in combinatie met methotrexaat, is geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten die onvoldoende hebben gereageerd op, of die intolerant zijn voor één of meerdere disease-modifying anti-reumatische drug (dmard) therapieën.

Europese Unie - Nederlands - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - hiv-infecties - antivirale middelen voor systemisch gebruik - trogarzo, in combinatie met andere antiretrovirale(s), is geïndiceerd voor de behandeling van volwassenen die besmet zijn met multiresistente hiv-1 infectie voor wie het anders niet mogelijk is om de bouw van een onderdrukkende antiviraal regime.

Europese Unie - Nederlands - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologica - lucentis is geïndiceerd bij volwassenen voor:de behandeling van neovascular (natte) leeftijdsgebonden maculaire degeneratie (amd)de behandeling van slechtziendheid als gevolg choroidale neovascularisation (cnv)de behandeling van slechtziendheid als gevolg diabetisch macula-oedeem (dme)de behandeling van slechtziendheid als gevolg van maculair oedeem, secundair aan retinale veneuze occlusie (tak rvo of centrale rvo).

Europese Unie - Nederlands - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologica - eylea is geïndiceerd bij volwassenen voor de behandeling van:neovascular (natte) leeftijdsgebonden maculaire degeneratie (amd);slechtziendheid als gevolg van maculair oedeem, secundair aan retinale veneuze occlusie (tak rvo of centrale rvo);visuele handicap vanwege diabetisch macula-oedeem (dme);visuele handicap vanwege bijziend choroidale neovascularisation (bijziend cnv).